HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Surindra N. Mitruka Si M. Pham Robert J. Keenan Bartley P. Griffith Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mitruka, S. N. Articles by Griffith, B. P. Search for Related Content PubMed PubMed Citation Articles by Mitruka, S. N. Articles by Griffith, B. P.

J Thorac Cardiovasc Surg 1998;115:28-37
© 1998 Mosby, Inc.

CARDIAC AND PULMONARY REPLACEMENT

Aerosol cyclosporine prevents acute allograft rejection in experimental lung transplantation

This research has been supported by National Institutes of Health grant RO1-HL48091-03.

Read at the Seventy-seventh Annual Meeting of The American Association for Thoracic Surgery, Washington, D.C., May 4-7, 1997.

Received for publication May 7, 1997; revisions requested June 16, 1997; revisions received Sept. 8, 1997; accepted for publication Sept. 9, 1997. Address for reprints: Bartley P. Griffith, MD, Professor of Surgery, Chief, Cardiothoracic Surgery, University of Pittsburgh School of Medicine Suite C-700 PUH, 200 Lothrop St., Pittsburgh, PA 15261.

Abstract

Background: The incidence of acute rejection and the morbidity of systemic cyclosporine (INN: ciclosporin) after lung transplantation is significant. Experimental evidence suggests that the allograft locally modulates the immune mechanisms of acute rejection. The purpose of this study was to determine whether aerosolized cyclosporine would prevent acute cellular rejection, achieve effective graft concentrations with low systemic drug delivery, and locally affect production of the inflammatory cytokines involved in acute rejection.
Methods: Unilateral orthotopic left lung transplantation was performed in 64 rats (ACI to Lewis), which were divided into eight groups (each group, n = 8): group A, no treatment; groups B to D, aerosol cyclosporine 1 to 3 mg/kg per day, respectively; groups E to H, systemic cyclosporine 2, 5, 10, and 15 mg/kg per day, respectively. After the animals were killed on postoperative day 2, 4, or 6, the transplanted lung, native lung, spleen, and blood were collected. Histologic studies, high-pressure liquid chromatography for trough cyclosporine concentrations, and reverse-transcriptase polymerase chain reaction for cytokine gene expression were performed.
Results: Untreated animals showed grade 4 rejection by postoperative day 6. Aerosol cyclosporine prevented acute rejection in a dose-dependent fashion, with group D animals (3 mg/kg per day) showing minimal grade 1 changes. Among animals receiving systemic cyclosporine, only group H (15 mg/kg per day) controlled (grade 1) rejection. However, aerosol cyclosporine, at an 80% lower dose, achieved significantly lower concentrations of cyclosporine in the graft (12,349 vs 28,714 ng/mg, p = 0.002004) and blood (725 vs 3306 ng/ml, p = 0.000378). Group F (systemic 5 mg/kg per day) had higher cyclosporine concentrations in the blood than group D (p = 0.004572) and similar tissue concentrations (p = 0.115180), yet had grade 2 rejection. Reverse-transcriptase polymerase chain reaction demonstrated equivalent suppression of inducible nitric oxide synthase but a 20- to 25-fold higher expression of interleukin-6, interleukin-10, and interferon- in group D versus group H recipient allografts.
Conclusion: Local delivery of cyclosporine by aerosol inhalation dose-dependently prevented acute pulmonary allograft rejection. Effective graft levels and low systemic drug delivery required significantly lower doses than systemic therapy alone. The gene expression of proinflammatory cytokines involved in allograft rejection was suppressed by aerosol cyclosporine therapy.

This article has been cited by other articles:

				N. Ide, T. Nagayasu, K. Matsumoto, T. Tagawa, K. Tanaka, T. Taguchi, Y. Sumida, and M. Nakashima Efficacy and safety of inhaled tacrolimus in rat lung transplantation J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 548 - 553. [Abstract] [Full Text] [PDF]

				K. S. Kunert, A. S. Tisdale, and I. K. Gipson Goblet Cell Numbers and Epithelial Proliferation in the Conjunctiva of Patients With Dry Eye Syndrome Treated With Cyclosporine Arch Ophthalmol, March 1, 2002; 120(3): 330 - 337. [Abstract] [Full Text] [PDF]

				G. V. Letsou, H. J. Safi, M. J. Reardon, M. Ergenoglu, Z. Li, C. N. Klonaris, J. C. Baldwin, B. E. Gilbert, and J. C. Waldrep Pharmacokinetics of liposomal aerosolized cyclosporine A for pulmonary immunosuppression Ann. Thorac. Surg., December 1, 1999; 68(6): 2044 - 2048. [Abstract] [Full Text] [PDF]